| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Cristina Álvarez-Escolá, Eva María Venegas-Moreno, Juan Antonio García-Arnés, Concepción Blanco-Carrera, Mónica Marazuela-Azpiroz, María Ángeles Gálvez-Moreno, Edelmiro Menéndez-Torre, Javier Aller-Pardo, Isabel Salinas-Vert, Eugenia Resmini, Elena María Torres-Vela, María Ángeles Gonzalo-Redondo, Ricardo Vílchez-Joya, María Paz de Miguel-Novoa, Irene Halperín-Rabinovich, Concepción Páramo-Fernández, Guillermo de la Cruz-Sugranyes, Aude Houchard, Antonio Miguel Picó-Alfons. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. Endocrinologia, diabetes y nutricion. vol 66. issue 5. 2019-12-16. PMID:30773338. |
the acrostart study was intended to determine the time to achieve normalization of gh and igf-i levels in responding patients with acromegaly administered different dosage regimens of lanreotide autogel (somatuline |
2019-12-16 |
2023-08-13 |
Not clear |
| Mirella Hage, Peter Kamenický, Philippe Chanso. Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions. Neuroendocrinology. vol 108. issue 3. 2019-12-09. PMID:30685760. |
besides the classical suppressive effects of glucose on gh release, a paradoxical gh increase to oral glucose may be observed in around one third of patients with acromegaly as well as in various other disorders. |
2019-12-09 |
2023-08-13 |
rat |
| Mirella Hage, Peter Kamenický, Philippe Chanso. Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions. Neuroendocrinology. vol 108. issue 3. 2019-12-09. PMID:30685760. |
a better understanding of the dynamics mediating gh response to glucose may allow a more optimal use of the ogtt as a diagnostic tool in various conditions, especially acromegaly. |
2019-12-09 |
2023-08-13 |
rat |
| Yu-Chen Chen, Hao-Wei Chen, Ming-Tan Chen, Chun-Hsiung Huang, Ching-Chia Li, Yung-Shun Juan, Hung-Lung K. Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5α-reductase inhibitors: A 15-year longitudinal case report. Lower urinary tract symptoms. vol 11. issue 2. 2019-12-06. PMID:29405593. |
transsphenoidal surgery, postoperative radiotherapy, and octreotide medical therapy failed to control the acromegaly, and growth hormone (gh) and insulin-like growth factor 1 (igf-1) levels remained elevated. |
2019-12-06 |
2023-08-13 |
Not clear |
| Yu-Chen Chen, Hao-Wei Chen, Ming-Tan Chen, Chun-Hsiung Huang, Ching-Chia Li, Yung-Shun Juan, Hung-Lung K. Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5α-reductase inhibitors: A 15-year longitudinal case report. Lower urinary tract symptoms. vol 11. issue 2. 2019-12-06. PMID:29405593. |
however, luts improved and prostate volume decreased markedly after 5α-reductase inhibitors were used, despite the poorly controlled acromegaly (elevated gh and igf-1 levels). |
2019-12-06 |
2023-08-13 |
Not clear |
| María Luisa Granad. Biochemical following-up of treated acromegaly. Limitations of the current determinations of IGF-I and perspective. Minerva endocrinologica. vol 44. issue 2. 2019-12-06. PMID:30311754. |
acromegaly is a rare disease caused by excess growth hormone (gh) secretion leading to an insulin-like growth factor-1 (igf-i) which is the major mediator of gh action. |
2019-12-06 |
2023-08-13 |
Not clear |
| María García-Álvarez, Vicente Climen. Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment. Minerva endocrinologica. vol 44. issue 2. 2019-12-06. PMID:30482010. |
acromegaly is a rare disease characterized by high levels of growth hormone (gh) and insulin-like growth factor 1 (igf-1). |
2019-12-06 |
2023-08-13 |
Not clear |
| Manuel Puig-Domingo, Monica Marazuel. Precision medicine in the treatment of acromegaly. Minerva endocrinologica. vol 44. issue 2. 2019-12-06. PMID:30531695. |
acromegaly is a chronic disorder usually diagnosed late in the disease evolution, leading to substantial morbidity and mortality related to this long period of undiagnosed state as well as the difficulty in achieving normalization of gh hypersecretion and controlling tumor mass. |
2019-12-06 |
2023-08-13 |
Not clear |
| Cristina Lamas, Araceli García-Martínez, Rosa Cámara, Carmen Fajardo-Montanana, Legna Viguera, Ignacio Arand. Silent somatotropinomas. Minerva endocrinologica. vol 44. issue 2. 2019-12-06. PMID:30531696. |
silent somatotroph pituitary neuroendocrine tumors (or silent growth hormone pituitary neuroendocrine tumors, sgh-pitnet) are neoplasias with positive immunostaining for growth hormone (gh), in patients with no signs and symptoms of acromegaly nor biochemical evidence of gh hypersecretion. |
2019-12-06 |
2023-08-13 |
Not clear |
| Antonio C Fuentes-Fayos, Araceli García-Martínez, Aura D Herrera-Martínez, Juan M Jiménez-Vacas, Mari C Vázquez-Borrego, Justo P Castaño, Antonio Picó, Manuel D Gahete, Raúl M Luqu. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva endocrinologica. vol 44. issue 2. 2019-12-06. PMID:30650942. |
acromegaly is a chronic systemic disease mainly caused by a growth hormone (gh)-secreting pituitary neuroendocrine tumor (pitnets), which is associated with many health complications and increased mortality when not adequately treated. |
2019-12-06 |
2023-08-13 |
Not clear |
| Katharina Schilbach, Christina Gar, Andreas Lechner, Shiva Sophia Nicolay, Laura Schwerdt, Michael Haenelt, Jakob Dal, Jens-Otto Lunde Jørgensen, Sylvère Störmann, Jochen Schopohl, Martin Bidlingmaie. Determinants of the growth hormone nadir during oral glucose tolerance test in adults. European journal of endocrinology. vol 181. issue 1. 2019-12-03. PMID:31096183. |
growth hormone (gh) nadir (ghnadir) during oral glucose tolerance test (ogtt) is an important tool in diagnosing acromegaly, but data evaluating the need to adjust cut-offs to biological variables utilizing today's assay methods are scarce. |
2019-12-03 |
2023-08-13 |
human |
| Mark L Hartman, Ali Iranmanesh, Michael O Thorner, Johannes D Veldhui. Evaluation of pulsatile patterns of growth hormone release in humans: A brief review. American journal of human biology : the official journal of the Human Biology Council. vol 5. issue 6. 2019-11-20. PMID:28548364. |
in diseases such as obesity, type i diabetes mellitus, hypo- and hyperthyroidism, turner's syndrome, uremia, liver failure, and acromegaly the pulsatile secretion of gh and/or its metabolic clearance rate are altered. |
2019-11-20 |
2023-08-13 |
human |
| M Galdiero, R Pivonello, L F S Grasso, A Cozzolino, A Cola. Growth hormone, prolactin, and sexuality. Journal of endocrinological investigation. vol 35. issue 8. 2019-11-20. PMID:28726215. |
sexual function in men and women with gh deficiency (ghd) and gh excess, particularly in acromegaly, is scantily studied and gh- or igf-i-dependent effects are difficult to quantify. |
2019-11-20 |
2023-08-13 |
Not clear |
| M Galdiero, R Pivonello, L F S Grasso, A Cozzolino, A Cola. Growth hormone, prolactin, and sexuality. Journal of endocrinological investigation. vol 35. issue 8. 2019-11-20. PMID:28726215. |
data on beneficial effects of gh replacement therapy and specific surgical or pharmacological approach for acromegaly are far to be fully elucidated although restoring normal gh/igf-i levels have been associated to improvement of sexual function. |
2019-11-20 |
2023-08-13 |
Not clear |
| b' Francesco Ferra\\xc3\\xb9, Adriana Albani, Alessandro Ciresi, Carla Giordano, Salvatore Cannav\\xc3\\xb. Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment. Frontiers in endocrinology. vol 9. 2019-11-20. PMID:30034367.' |
acromegaly is a rare disease due to chronic gh excess and to the consequent increase in igf-1 levels. |
2019-11-20 |
2023-08-13 |
Not clear |
| C Bima, S Chiloiro, M Mormando, S Piacentini, E Bracaccia, A Giampietro, L Tartaglione, A Bianchi, L De Marini. Understanding the effect of acromegaly on the human skeleton. Expert review of endocrinology & metabolism. vol 11. issue 3. 2019-11-20. PMID:30058934. |
acromegaly, caused in most cases by growth hormone (gh)-secreting pituitary adenomas, is characterized by increased skeletal growth and enlargement of the soft tissue, because gh and its effector insulin-like growth factor-1 are important regulators of bone homeostasis and have a central role in the longitudinal bone growth and maintenance of bone mass. |
2019-11-20 |
2023-08-13 |
human |
| Kim Mja Claessen, Alberto M Pereira, Nienke R Biermas. Outcome of complications in acromegaly patients after long-term disease remission. Expert review of endocrinology & metabolism. vol 10. issue 5. 2019-11-20. PMID:30298766. |
acromegaly patients suffer from pathologically high growth hormone (gh) and igf-1 levels that in 99% of cases is due to a gh-producing pituitary adenoma. |
2019-11-20 |
2023-08-13 |
Not clear |
| Kevin Cj Yuen, Vera Popovi. Growth hormone replacement in patients with a history of malignancy: a review of the literature and best practice for offering treatment. Expert review of endocrinology & metabolism. vol 10. issue 3. 2019-11-20. PMID:30298774. |
evidence supporting this notion is derived from animal studies, epidemiological observations, patients with acromegaly and from therapeutic manipulation of gh and igf-i actions. |
2019-11-20 |
2023-08-13 |
Not clear |
| Bernd W. Scheithauer, Kalman T. Kovacs, Lucia Stefaneanu, Eva Horvath, Laurie A. Kane, William F. Young, Ricardo V. Lloyd, Raymond V. Randall, Dudley H. Davi. The Pituitary in Gigantism. Endocrine pathology. vol 6. issue 3. 2019-11-20. PMID:12114738. |
to compare the pituitary pathology of gigantism to that of acromegaly, 19 surgically resected lesions were studied from 10 males and 9 females, ages 13-49 (mean, 19 yr) with excessive height (>/=95th percentile), onset of disease prior to puberty, elevated growth hormone (gh) levels despite glucose suppression, and a pathologically confirmed gh-producing pituitary mass. |
2019-11-20 |
2023-08-12 |
human |
| Verena Gounden, Yashna D Rampursat, Ishwarlal Jiala. Secretory tumors of the pituitary gland: a clinical biochemistry perspective. Clinical chemistry and laboratory medicine. vol 57. issue 2. 2019-10-28. PMID:30120907. |
acromegaly can be diagnosed by basal insulin growth-like factor 1 levels and the failure of growth hormone (gh) to suppress during an oral glucose tolerance test. |
2019-10-28 |
2023-08-13 |
Not clear |